Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
LA JOLLA, Calif. , January 13, 2009
Burnham Institute for Medical Research (Burnham) has signed an assay development and license agreement with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). The agreement is Burnham’s first broad-based partnership with a large pharmaceutical company.
Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.
“This collaboration offers great synergies,” said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. “Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential.